Ondine Biomedical Inc - Asset Resilience Ratio

Latest as of September 2008: 39.85%

Ondine Biomedical Inc (OBI) has an Asset Resilience Ratio of 39.85% as of September 2008. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Ondine Biomedical Inc (OBI) financial obligations for a breakdown of total debt and financial obligations.

Liquid Assets

GBX1.88 Million

≈ $228.22 USD Cash + Short-term Investments

Total Assets

GBX4.71 Million

≈ $572.65 USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2006–2007)

This chart shows how Ondine Biomedical Inc's Asset Resilience Ratio has changed over time. See OBI net asset value for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Ondine Biomedical Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see OBI market cap overview.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	GBX0.00	0%
Short-term Investments	GBX1.88 Million	39.85%
Total Liquid Assets	GBX1.88 Million	39.85%

Asset Resilience Insights

Very High Liquidity: Ondine Biomedical Inc maintains exceptional liquid asset reserves at 39.85% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Ondine Biomedical Inc Industry Peers by Asset Resilience Ratio

Compare Ondine Biomedical Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Royalty Pharma Plc NASDAQ:RPRX	Biotechnology	0.10%
Ascendis Pharma AS NASDAQ:ASND	Biotechnology	0.00%
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	3.28%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	4.52%
Ligand Pharmaceuticals Incorporated NASDAQ:LGND	Biotechnology	35.56%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Jiangsu Aidea Pharmaceutical Co Ltd SHG:688488	Biotechnology	4.35%

Annual Asset Resilience Ratio for Ondine Biomedical Inc (2006–2007)

The table below shows the annual Asset Resilience Ratio data for Ondine Biomedical Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2007-12-31	43.12%	GBX5.61 Million ≈ $682.19	GBX13.00 Million ≈ $1.58K	-15.66pp
2006-12-31	58.78%	GBX10.85 Million ≈ $1.32K	GBX18.46 Million ≈ $2.25K	--

pp = percentage points

About Ondine Biomedical Inc

LSE:OBI UK Biotechnology

Market Cap

$741.08K

GBX6.09 Billion GBX

Market Cap Rank

#30373 Global

#850 in UK

Share Price

GBX11.75

Change (1 day)

+0.00%

52-Week Range

GBX8.00 - GBX18.00

All Time High

GBX58.50